Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference

Drug ApprovalGene Therapy
Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference
PITTSBURGH, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the TD Cowen 44th Annual Health Care Conference, which takes place in Boston on March 4-6.
Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in a fireside chat at 9:50 am ET during the conference and host investor meetings on March 5.
A webcast of the presentation will be available here beginning at 9:50 am ET on Tuesday, March 5 and will be posted on the Investors section of the Company’s website.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).
CONTACT:
Investors and Media
Meg Dodge
mdodge@krystalbio.com


The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.